Alzheimer's disease, a progressive neurodegenerative disease, is characterised by
hypofunction of acetylcholine (ACh) neurotransmitter in the distinct region of brain …

Acetylcholinesterase (AChE), the predominant cholinesterase in the brain, hydrolyzes ACh
to choline and acetate, thereby terminating the effect of this neurotransmitter at cholinergic …

Background Alzheimer's disease (AD) is a neurodegenerative disease caused by the
formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Acetylcholinesterase …

Inhibition of acetylcholinesterase (AChE), the key enzyme in the breakdown of acetylcholine,
is considered as a promising strategy for the treatment of neurological disorders such as …

As acetylcholinesterase (AChE) inhibitors are an important therapeutic strategy in
Alzheimer's disease, efforts are being made in search of new molecules with anti-AChE …

Abstract Alzheimer's disease (AD), is the most common type of dementia primarily affecting
the later years of life. Its prevalence is likely to increase in any aging population and will be a …

The predominant role of the central cholinergic pathway in learning and memory and the
creation of severe cholinergic deficits with several neurodegenerative disorders and …

The inhibition of acetylcholinesterase (AChE) has been one of the most used strategies for
the treatment of Alzheimer's disease (AD). The AChE inhibitors (AChE-I) produce not only …

Acetylcholinesterase (AChE)(EC 3.1. 1.7) is an important enzyme that breaks down of
acetylcholine in synaptic cleft in neuronal junctions. Inhibition of AChE is associated with …

Acetylcholinesterase (AChE) inhibitors are considered as promising therapeutic agents for
the treatment of several neurological disorders such as Alzheimer's disease (AD), senile …